Amneal Pharmaceuticals Stock Earnings Reports

Amneal announced an agreement to acquire Kashiv BioSciences to create a vertically integrated global biosimilars leader. The deal combines Kashiv's R&D and biologics manufacturing (capacity scaling from ~26kL in 2026 to ~75kL by 2028) with Amneal's commercial scale and specialty infrastructure, adding a 20+ biosimilar program portfolio that targets >$100B in U.S. opportunity. Preliminary Q1 results were strong: revenue +4% to $723M, adjusted EBITDA +19% to $202M, adjusted EPS +29% to $0.27, and net leverage improved to 3.5x. Amneal raised its stand-alone 2026 guidance and expects modest near-term cash impact from transaction/integration costs. Deal economics: $750M upfront (50% cash / 50% equity, ~8% dilution) plus up to $350M in regulatory milestones and potential royalties; funded by cash on hand and incremental debt. Management expects $400M–$500M of cumulative financial synergies over time, a deleveraging path to ~3.0x net debt/EBITDA by 2028, and substantial long-term growth (combined revenue projected to grow ~40% (~$1.2B) by 2030 vs. 2026, and EPS +~$0.70). Near-term biosimilar catalysts include lanreotide (expected Q3 approval) and XOLAIR (anticipated year-end approval); Kashiv can support 3–5 biosimilar developments per year. Company-wide gross margins are improving (2025: ~43% vs. 2026 outlook ~45%), driven by higher-margin specialty and Affordable Medicines mix and improved AvKARE margins. Management frames the acquisition as strategically de-risked given a 10+ year partnership with Kashiv and intends to focus U.S. commercialization directly while partnering internationally where appropriate.